Q3 EPS Estimate for Aura Biosciences Increased by Analyst

Key Points

• Analysts at Leerink Partners have raised their Q3 2025 earnings per share estimate for Aura Biosciences from ($0.51) to ($0.46).
• Aura Biosciences reported Q3 earnings of ($0.47) per share, slightly outperforming the analysts' consensus estimate of ($0.49).
• The company has received a consensus "Buy" rating from analysts, with a target price of $22.00 per share.

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Aura Biosciences in a note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($0.46) per share for the quarter, up from their previous estimate of ($0.51). The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences' Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.98) EPS and FY2026 earnings at ($2.30) EPS.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02.

Other analysts have also recently issued research reports about the company. JMP Securities reiterated a "market outperform" rating and set a $19.00 price objective on shares of Aura Biosciences in a research report on Friday, May 23rd. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Wednesday, August 13th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Aura Biosciences presently has a consensus rating of "Buy" and a consensus target price of $22.00.

Aura Biosciences Trading Down 4.0%

Aura Biosciences stock opened at $6.72 on Monday. The stock has a market cap of $417.45 million, a PE ratio of -3.43 and a beta of 0.46. The stock has a 50-day moving average price of $6.62 and a 200 day moving average price of $6.51. Aura Biosciences has a 52 week low of $4.34 and a 52 week high of $12.38.

Hedge Funds Weigh In On Aura Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of AURA. Tower Research Capital LLC TRC lifted its position in Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after acquiring an additional 2,104 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Aura Biosciences during the 4th quarter worth approximately $50,000. GAMMA Investing LLC lifted its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after acquiring an additional 9,573 shares in the last quarter. Invesco Ltd. acquired a new position in Aura Biosciences during the 2nd quarter worth approximately $76,000. Finally, Bridgeway Capital Management LLC acquired a new position in Aura Biosciences during the 2nd quarter worth approximately $102,000. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.